Hebrew University of Jerusalem has spun off a start-up nanotech company with new technology for the release of lipophilic drugs. The university's tech transfer company, Yissum, created Nanolymf from new technology developed by Prof. Simon Benita at the Hebrew University's School of Pharmacy. "The ability to deliver lipophilic drugs orally while bypassing specific potent barriers in the intestine and the liver carries tremendous potential," says Nava Swersky Sofer, CEO of Yissum. "Professor Benita, a seasoned inventor and entrepreneur and the founder of Novagali SA, one of Yissum's most promising spin-offs, has once again demonstrated his ingenuity in developing a novel mechanism addressing many unmet medical needs." Release